Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2023 | ARASENS: tolerability + pharmacokinetic analyses of combo therapy with DARO, ADT and DOC in mHSPC

Bertrand Tombal, MD, PhD, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium, provides an overview of a tolerability and pharmacokinetic analyses of combination therapy with darolutamide, androgen-deprivation therapy, and docetaxel in patients with metastatic hormone sensitive prostate cancer (mHSPC) from the Phase III ARASENS (NCT02799602) trial. The trial observed there was no added toxicities with the addition of dialuramide to docetaxel. This interview took place at the EAU congress in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.